Liminatus Pharma, Inc.
LIMN
$0.65
-$0.06-8.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -203.19% | 92.12% | -50.00% | 70.30% | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -- | -- | -- | -- | |
| Change in Net Operating Assets | -69.87% | -565.21% | 50.00% | -80.53% | |
| Cash from Operations | -191.41% | -712.81% | -- | 55.80% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 100.00% | 48.33% | -- | -17.27% | |
| Cash from Investing | 98.36% | 48.33% | -- | -17.27% | |
| Total Debt Issued | -100.00% | 93.75% | -- | -50.00% | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -100.00% | -7,021.39% | -- | -- | |
| Cash from Financing | -100.00% | 400.58% | -- | -41.67% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -4,857.36% | 420.23% | -- | -97.82% | |